Glioblastoma, High-grade Glioma
Conditions
Keywords
Fluorescence guided surgery, Glioblastoma, High-grade glioma, 5-ALA
Brief summary
The MIRROR study is a prospective, single center phase I feasibility and dose finding study in patients with high-grade glioma, to establish the safety, feasibility, and optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery, in comparison to the standard of care (SOC), 5-ALA fluorescent imaging agent. The main research objectives of this study are: 1. To determine the optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery 2. To assess the safety and tolerability 3. To correlate fluorescent signals measured by in vivo multispectral imaging with Cetuximab-IRDye800CW and 5-ALA with those measured by ex vivo imaging The study population will consist of patients, aged ≥18 years, diagnosed with high-grade glioma and scheduled for surgery.
Interventions
patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
Sponsors
University Medical Center Groningen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
prospective, single center phase I feasibility and dose finding study in a single cohort, i.e patients with glioblastoma
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing to adhere to the prohibitions and restrictions specified in this protocol. * Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol. * Patients aged ≥ 18 years inclusive at moment signing informed consent form. * Established high-grade glioma (glioblastoma, grade 4 according to the WHO (World Health Organization) classification) and scheduled for surgical intervention. * Life expectancy of \> 12 weeks. * Karnofsky performance status of at least 70%. * No clinically significant laboratory abnormalities as determined by the investigator o Note: one retest of lab tests is allowed within the screening window * Female patients should fulfil one of the following criteria: * At least 1 year post-menopausal (amenorrhea \>12 months) at screening * Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation) * Women \>18 years of age who are fertile, need to agree to use an adequate form of contraceptives during and till 3 months after the study. Before study enrollment, a pregnancy test in blood or urine will be performed to rule out a pregnancy. In the case of an unlikely pregnancy during the study, they accept the possible maternal/ fetal risk of participation in the study.
Exclusion criteria
General: * Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the patient to understand and cooperate with the study protocol * Deprived of freedom by an administrative or court order or in an emergency setting. * Insufficient venous access for the study procedures. * Close affiliation with the investigator; e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of Neurosurgery of the UMCG (University Medical Center Groningen), or affiliates * Any finding in the medical examinations or medical history giving, that in the opinion of the investigator, leads to a reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications * Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device Medical conditions * Concomitant malignancies, including metastasized colon-, rectal-, breast carcinoma, non-small cellular lung carcinoma (NSCLC); primary epithelial ovarian-, fallopian tube-, primary peritoneal- or cervical carcinoma. * Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate * eGFR (based on plasma-creatinine) outside of normal range at screening or known renal impairment (≤40 mL/min). * Current evidence or history of bacterial, viral or fungal infections within 7 days before Cetuximab-IRDye800CW administration, as judged by the Investigator. o T \> = 38.0°C or lab confirmed viral/bacterial/fungal infection (PCR)) or symptoms suggestive of an infection) * Any laboratory test which is abnormal, and which is deemed by the Investigator(s) to be clinically significant * A history of anaphylaxis, history of allergic reaction(s), known allergy to one of the drugs or excipients administered as part of this study. Mild allergies without angioedema or treatment need can be acceptable if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal dosage | 1 day | To determine the optimal dosage of Cetuximab-IRDye800CW for fluorescence guided surgery of high-grade glioma using Near- Infrared (NIR) fluorescence imaging |
| To assess the safety and tolerability of intravenous tracer administration by measuring/registering the number(S)AEs and SUSARs that have occurred during the duration of the trial | 4-5 days | The (S)AEs and SUSARS will be reported according to the CTCAE v4.0 |
| In vivo/ex vivo correlation | 1 day | To correlate fluorescent signals measured by in vivo multispectral imaging with Cetuximab-IRDye800CW and 5-ALA with those measured by ex vivo imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fluorescent signals vs pathology | 1 day | To correlate the presence of pathologically confirmed EGFR(epidermal growth factor receptor)-gene amplification with the presence of fluorescence signals, in- and ex vivo, as measured with NIR fluorescent imaging after administering Cetuximab-IRDye800CW. |
| DSC biomarkers | 1 day | Correlation between DSC (dynamic susceptibility contrast) biomarkers with pathological EGFR-gene amplification status. |
Countries
Netherlands
Contacts
Primary ContactYester Janssen, MD
Outcome results
None listed